Author: Mirjana Bjelos (Croatia)
Co-authors: Gabriella Germán, Natalia Filimonova, Beata Busanyova
Purpose
Voretigene neparvovec (VN) is the first ocular gene therapy approved for the treatment of patients with visual impairment due to confirmed biallelic RPE65 mutation-associated inherited retinal dystrophy (IRD) and who have sufficient viable retinal cells. Due to the novelty of the treatment and the limited number of patients, VN is administered in treatment centers that fulfill specified European Union (EU)-mandated risk mitigation criteria. This also ensures that safety and efficacy are kept a top priority. EU regulation and directive furthermore govern planned cross-border interventions, under which a patient may travel to another EU country to receive treatment, and have the cost reimbursed by their own health insurance scheme. Herein, we present the experience of, and coordination between, a VN treatment center in Croatia and a patient management center in Slovakia.
Setting/Venue
Cross-border ocular gene therapy treatment and management between the University Eye Department, University Hospital “Sveti Duh”, Zagreb (UEDUHSDZ), Croatia and the National Institute of Children’s Diseases (NICHD), Faculty of Medicine, Comenius University, Bratislava, Slovakia, following S2 form authorization. The S2 (formerly E 112) form is issued by the health insurance authority in the patient’s home country to permit planned healthcare treatment in another EU country. The form is then submitted to the health insurance authority in the treating country.
Methods
The IRD registry at the NICHD, Slovakia was retrospectively evaluated to identify patients diagnosed with IRD owing to RPE65 mutations, as confirmed by genetic analysis and segregation analysis of first degree relatives. Five pediatric patients were identified, with two patients subsequently recommended as suitable for VN treatment following examination of visual acuity (VA), fundoscopy, wide-field fundus photography (WFFP), autofluorescence, perimetry, optical coherence tomography (OCT), color vision (CV), contrast sensitivity (CS), visually evoked potentials (VEP), electroretinography (ERG), tonometry, biometry, refraction and a visual function questionnaire. Three certified VN treatment centers in the EU were contacted to participate in the cross-border care of the two NICHD patients. UEDUHSDZ, Croatia accepted NICHD’s treatment application and a cross-border treatment agreement was established. As VN treatment is covered by health insurance in Slovakia, prior reimbursement authorization was requested and a S2 form was issued. Patients were referred to the multidisciplinary team in UEDUHSDZ, which comprises a pediatric ophthalmologist, an IRD specialist, three retinal surgeons with experience in subretinal application and a geneticist. Surgery was scheduled in Croatia in December 2020, with patients enrolled in PERCEIVE (a post-authorization, multicenter, multinational, longitudinal, observational safety registry study for patients treated with VN) by their managing physician in Slovakia.
Results
Following a negative COVID-19 PCR test, both patients were admitted to UEDUHSDZ four days prior to their scheduled surgical procedure. Patients were examined by the multidisciplinary team in UEDUHSDZ, with WFFP, autofluorescence, biometry, tonometry and OCT performed to confirm eligibility for VN treatment. An immunomodulatory regimen was subsequently initiated in accordance with the recommended VN product information pre-operative schedule. On day four, patients received 300 μl of VN in the first (more severely affected) eye, followed by treatment of the contralateral eye, one week later. Post-surgery, information on the procedure was immediately communicated to NICHD to update the PERCEIVE registry. Patients were discharged from UEDUHSDZ four days after their second surgery and presented to NICHD 30 days post-operatively for follow-up clinical examinations. Follow-up assessment revealed a significant improvement in central visual acuity in one of the two patients, with both patients reporting an improvement in quality of life. No adverse events were observed. The patients will be further followed by NICHD at month 3, month 6 and 1 year.
Conlusions
A willingness to collaborate, straightforward funding arrangements and positive relations between the Croatian and Slovakian teams contributed to the successful cross-border treatment and management of patients. In this case example, patients were diagnosed with biallelic RPE65 mutation-associated IRDs by the multidisciplinary team at the NICHD, Bratislava and referred to UEDUHSDZ, Croatia for VN surgical treatment. Following successful gene therapy administration in UEDUHSDZ, patients were discharged and returned to Bratislava for post-operative follow-up at the NICHD. Communication and collaboration between UEDUHSDZ and NICHD was seamless and efficient, with a positive cross-border experience reported by the patients, families and both multidisciplinary teams. Due to treatment and management center cooperation and positive collaboration, a further three patients from the NICHD IRD registry will be evaluated for cross-border VN treatment.
Financial Disclosure
Mirjana Bjeloš: Voretigene neparvovec post-authorisation safety study (PASS) principle investigator; Beata Busanyova: Voretigene neparvovec post-authorisation safety study (PASS) principle investigator; Natalia Filimonova: Employee of Novartis; Gabriella Germán: Employee of Novartis
Comments
-